The Second-Generation Maturation Inhibitor GSK3532795 Maintains Potent Activity Toward HIV Protease Inhibitor–Resistant Clinical Isolates

BACKGROUND: Protease inhibitor (PI)-resistant HIV-1 isolates with primary substitutions in protease (PR) and secondary substitutions in Gag could potentially exhibit cross-resistance to maturation inhibitors. We evaluated the second-generation maturation inhibitor, GSK3532795, for activity toward cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Ray, Neelanjana, Li, Tianbo, Lin, Zeyu, Protack, Tricia, van Ham, Petronella Maria, Hwang, Carey, Krystal, Mark, Nijhuis, Monique, Lataillade, Max, Dicker, Ira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JAIDS Journal of Acquired Immune Deficiency Syndromes 2017
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5389583/
https://www.ncbi.nlm.nih.gov/pubmed/28234686
http://dx.doi.org/10.1097/QAI.0000000000001304

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5389583/
https://www.ncbi.nlm.nih.gov/pubmed/28234686
http://dx.doi.org/10.1097/QAI.0000000000001304

Ejemplares similares